HAMBURG (dpa-AFX) - The collaboration between the drug discovery and development company Evotec and the US pharmaceutical company Bristol Myers Squibb (BMS) continues to bear fruit. Evotec will receive 25 million US dollars to drive further research, the MDax-listed company announced in Hamburg on Monday. In March 2023, the companies extended their collaboration on drug discovery in the field of neurological diseases, which had already been concluded in 2016, by eight years. Over time, performance-based milestone payments and tiered license fees up to a low double-digit percentage on product sales will be paid. At the time, Evotec put the total potential volume including upfront, license and milestone payments as well as royalties at four billion dollars (3.7 billion euros)./lew/mis